雷珠单抗-话题@MedSci

#雷珠单抗#

13篇内容 | 1434人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2165230, encodeId=467a21652305b, content=<a href='/topic/show?id=077112e9237' target=_blank style='color:#2F92EE;'>#NICE#</a> <a href='/topic/show?id=b0da98838c7' target=_blank style='color:#2F92EE;'>#雷珠单抗#</a>治疗<a href='/topic/show?id=371de681325' target=_blank style='color:#2F92EE;'>#糖尿病黄斑水肿#</a>, objectTitle=2023 NICE 技术鉴定指南：雷珠单抗治疗糖尿病黄斑水肿, objectType=guider, longId=26795, objectId=8e46f1c003a156e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/guideline/show_article.do?id=8e46f1c003a156e0, replyNumber=0, likeNumber=104, createdTime=2023-10-27, rootId=0, userName=litao2022, userId=1ff65466529, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=8e46f1c003a156e0, moduleTitle=2023 NICE 技术鉴定指南：雷珠单抗治疗糖尿病黄斑水肿, moduleType=guider, hrefUrl=https://www.medsci.cn/guideline/show_article.do?id=8e46f1c003a156e0)], followStatus=false, userIsMember=true, type=1, lengthMark=0), GetTopicListResponse(id=1507053, encodeId=413d150e0536a, content=<a href='/topic/show?id=b0da98838c7' target=_blank style='color:#2F92EE;'>#雷珠单抗#</a>, objectTitle=雷珠单抗和阿柏西普的新对手它将如何改变湿性AMD市场格局？, objectType=article, longId=184126, objectId=0fa6184126ad, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0fa6184126ad, replyNumber=0, likeNumber=109, createdTime=2019-12-05, rootId=0, userName=shanyongle, userId=01ea9855129, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0fa6184126ad, moduleTitle=雷珠单抗和阿柏西普的新对手它将如何改变湿性AMD市场格局？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0fa6184126ad)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1507052, encodeId=75ae150e052d8, content=<a href='/topic/show?id=b0da98838c7' target=_blank style='color:#2F92EE;'>#雷珠单抗#</a>, objectTitle=雷珠单抗在华4大适应症全部进入医保！, objectType=article, longId=183757, objectId=6684183e57bb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6684183e57bb, replyNumber=0, likeNumber=77, createdTime=2019-11-30, rootId=0, userName=shanyongle, userId=01ea9855129, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6684183e57bb, moduleTitle=雷珠单抗在华4大适应症全部进入医保！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6684183e57bb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1507051, encodeId=a2eb150e051f9, content=<a href='/topic/show?id=b0da98838c7' target=_blank style='color:#2F92EE;'>#雷珠单抗#</a>, objectTitle=Lancet：雷珠单抗治疗早产儿视网膜病变, objectType=article, longId=181998, objectId=833718199825, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=833718199825, replyNumber=0, likeNumber=83, createdTime=2019-10-28, rootId=0, userName=shanyongle, userId=01ea9855129, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=833718199825, moduleTitle=Lancet：雷珠单抗治疗早产儿视网膜病变, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=833718199825)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1507050, encodeId=7978150e05026, content=<a href='/topic/show?id=b0da98838c7' target=_blank style='color:#2F92EE;'>#雷珠单抗#</a>, objectTitle=Eur J Ophthalmol：玻璃体内注射超低剂量雷珠单抗治疗早产1型视网膜病变的疗效, objectType=article, longId=153884, objectId=507c153884ca, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=507c153884ca, replyNumber=0, likeNumber=105, createdTime=2018-11-20, rootId=0, userName=shanyongle, userId=01ea9855129, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=507c153884ca, moduleTitle=Eur J Ophthalmol：玻璃体内注射超低剂量雷珠单抗治疗早产1型视网膜病变的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=507c153884ca)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1507049, encodeId=20f9150e04940, content=<a href='/topic/show?id=b0da98838c7' target=_blank style='color:#2F92EE;'>#雷珠单抗#</a>, objectTitle=Ophthalmologica：治疗近视性脉络膜新血管形成的雷珠单抗的两种不同初始给药方案治疗结果相似！, objectType=article, longId=112635, objectId=d3d811263516, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d3d811263516, replyNumber=0, likeNumber=80, createdTime=2017-09-13, rootId=0, userName=shanyongle, userId=01ea9855129, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d3d811263516, moduleTitle=Ophthalmologica：治疗近视性脉络膜新血管形成的雷珠单抗的两种不同初始给药方案治疗结果相似！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d3d811263516)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1507048, encodeId=f085150e04812, content=<a href='/topic/show?id=b0da98838c7' target=_blank style='color:#2F92EE;'>#雷珠单抗#</a>, objectTitle=湿性老年黄斑变性一线药物雷珠单抗被纳入国家医保目录, objectType=article, longId=106647, objectId=db2810664e8c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=db2810664e8c, replyNumber=0, likeNumber=80, createdTime=2017-07-27, rootId=0, userName=shanyongle, userId=01ea9855129, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=db2810664e8c, moduleTitle=湿性老年黄斑变性一线药物雷珠单抗被纳入国家医保目录, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=db2810664e8c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1507047, encodeId=ec47150e04740, content=<a href='/topic/show?id=b0da98838c7' target=_blank style='color:#2F92EE;'>#雷珠单抗#</a>, objectTitle=第5个适应症！罗氏眼科药物Lucentis（雷珠单抗）获美国FDA批准治疗近视性脉络膜新生血管（mCNV）, objectType=article, longId=86943, objectId=563e86943ab, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=563e86943ab, replyNumber=0, likeNumber=62, createdTime=2017-01-09, rootId=0, userName=shanyongle, userId=01ea9855129, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=563e86943ab, moduleTitle=第5个适应症！罗氏眼科药物Lucentis（雷珠单抗）获美国FDA批准治疗近视性脉络膜新生血管（mCNV）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=563e86943ab)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1507046, encodeId=256b150e04687, content=<a href='/topic/show?id=b0da98838c7' target=_blank style='color:#2F92EE;'>#雷珠单抗#</a>, objectTitle=Ophthalmic Surg Lasers Imaging Retina：雷珠单抗治疗DME：0.5 mg vs. 1 mg, objectType=article, longId=72653, objectId=310ae265376, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=310ae265376, replyNumber=0, likeNumber=93, createdTime=2016-07-14, rootId=0, userName=shanyongle, userId=01ea9855129, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=310ae265376, moduleTitle=Ophthalmic Surg Lasers Imaging Retina：雷珠单抗治疗DME：0.5 mg vs. 1 mg, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=310ae265376)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1507045, encodeId=5b87150e0450f, content=<a href='/topic/show?id=b0da98838c7' target=_blank style='color:#2F92EE;'>#雷珠单抗#</a>, objectTitle=BMJ研究新闻：对于中重度糖尿病性黄斑水肿患者，阿柏西普的治疗效果优于贝伐单抗及雷珠单抗, objectType=article, longId=63953, objectId=41d26395382, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=41d26395382, replyNumber=0, likeNumber=71, createdTime=2016-03-02, rootId=0, userName=shanyongle, userId=01ea9855129, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=41d26395382, moduleTitle=BMJ研究新闻：对于中重度糖尿病性黄斑水肿患者，阿柏西普的治疗效果优于贝伐单抗及雷珠单抗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=41d26395382)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1507044, encodeId=8402150e04470, content=<a href='/topic/show?id=b0da98838c7' target=_blank style='color:#2F92EE;'>#雷珠单抗#</a>, objectTitle=OPHTHALMOLOGY：雷珠单抗后早期或后期激光治疗的比较, objectType=article, longId=12044, objectId=ae6412044d4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae6412044d4, replyNumber=0, likeNumber=84, createdTime=2012-11-30, rootId=0, userName=shanyongle, userId=01ea9855129, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae6412044d4, moduleTitle=OPHTHALMOLOGY：雷珠单抗后早期或后期激光治疗的比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae6412044d4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1507043, encodeId=4f12150e04358, content=<a href='/topic/show?id=b0da98838c7' target=_blank style='color:#2F92EE;'>#雷珠单抗#</a>, objectTitle=BMJ:贝伐珠单抗和雷珠单抗治疗糖尿病黄斑水肿无显著性差异, objectType=article, longId=9014, objectId=b7e790149f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b7e790149f, replyNumber=0, likeNumber=78, createdTime=2012-08-17, rootId=0, userName=shanyongle, userId=01ea9855129, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b7e790149f, moduleTitle=BMJ:贝伐珠单抗和雷珠单抗治疗糖尿病黄斑水肿无显著性差异, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b7e790149f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1507042, encodeId=40a9150e0425b, content=<a href='/topic/show?id=b0da98838c7' target=_blank style='color:#2F92EE;'>#雷珠单抗#</a>, objectTitle=FDA推荐雷珠单抗治疗糖尿病黄斑水肿, objectType=article, longId=8616, objectId=88d586166c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=88d586166c, replyNumber=0, likeNumber=104, createdTime=2012-08-08, rootId=0, userName=shanyongle, userId=01ea9855129, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=88d586166c, moduleTitle=FDA推荐雷珠单抗治疗糖尿病黄斑水肿, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=88d586166c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

雷珠单抗

2020-05-29

(审核中...)

前往app查看评论内容

#NICE# #雷珠单抗#治疗#糖尿病黄斑水肿#

2023 NICE 技术鉴定指南：雷珠单抗治疗糖尿病黄斑水肿

2023-10-27发表于上海

shanyongle (审核中...)

前往app查看评论内容

#雷珠单抗#

雷珠单抗和阿柏西普的新对手它将如何改变湿性AMD市场格局？

2019-12-05

shanyongle (审核中...)

前往app查看评论内容

#雷珠单抗#

雷珠单抗在华4大适应症全部进入医保！

2019-11-30

shanyongle (审核中...)

前往app查看评论内容

#雷珠单抗#

Lancet：雷珠单抗治疗早产儿视网膜病变

2019-10-28

shanyongle (审核中...)

前往app查看评论内容

#雷珠单抗#

Eur J Ophthalmol：玻璃体内注射超低剂量雷珠单抗治疗早产1型视网膜病变的疗效

2018-11-20

shanyongle (审核中...)

前往app查看评论内容

#雷珠单抗#

Ophthalmologica：治疗近视性脉络膜新血管形成的雷珠单抗的两种不同初始给药方案治疗结果相似！

2017-09-13

shanyongle (审核中...)

前往app查看评论内容

#雷珠单抗#

湿性老年黄斑变性一线药物雷珠单抗被纳入国家医保目录

2017-07-27

shanyongle (审核中...)

前往app查看评论内容

#雷珠单抗#

第5个适应症！罗氏眼科药物Lucentis（雷珠单抗）获美国FDA批准治疗近视性脉络膜新生血管（mCNV）

2017-01-09

shanyongle (审核中...)

前往app查看评论内容

#雷珠单抗#

Ophthalmic Surg Lasers Imaging Retina：雷珠单抗治疗DME：0.5 mg vs. 1 mg

2016-07-14

shanyongle (审核中...)

前往app查看评论内容

#雷珠单抗#

BMJ研究新闻：对于中重度糖尿病性黄斑水肿患者，阿柏西普的治疗效果优于贝伐单抗及雷珠单抗

2016-03-02

shanyongle (审核中...)

前往app查看评论内容

#雷珠单抗#

OPHTHALMOLOGY：雷珠单抗后早期或后期激光治疗的比较

2012-11-30

shanyongle (审核中...)

前往app查看评论内容

#雷珠单抗#

BMJ:贝伐珠单抗和雷珠单抗治疗糖尿病黄斑水肿无显著性差异

2012-08-17

shanyongle (审核中...)

前往app查看评论内容

#雷珠单抗#

FDA推荐雷珠单抗治疗糖尿病黄斑水肿

2012-08-08

科室
- - 订阅+
  - 更多科室
工具
服务